Metro Health Debuts New Peripheral Vascular Device
Metro Health Hospital announced today that it is the first hospital in West Michigan to use a new stent in the fight against amputation resulting from peripheral vascular disease and critical limb ischemia.
The Zilver® PTX® drug-eluting stent combines the benefits of mechanical and drug therapies to provide physicians and patients with longer-lasting results in the superficial femoral artery. It has been studied for more than 10 years and was approved for use in the superficial femoral artery, or SFA, just two months ago.
“I’m excited that we can offer Metro patients this new technology,” said Dr. Fadi Saab, an interventional cardiologist with Metro Health. “This is one more tool in our amputation-prevention tool box. Too often, patients with critical limb ischemia face the threat of a major amputation. We want to restore and maintain blood flow for these patients to help avoid amputation.”
Stents have long been used in coronary arteries to restore blood flow through the heart. Regular stents have limitations in treating femoral arteries. Regular non-medicated stents hold the vessel open, but sometimes reocclude because of the body’s natural reaction to a metal object in the vessel. The Zilver PTX stent contains time-release drugs that improve the chance of maintaining the vessel open.
Within the last two years, Metro Health’s interventional cardiovascular team has been either the first in the nation or the first in the region to debut new, innovative surgical devices shortly after being awarded approval from the U.S. Food and Drug Administration,
More than 17 million people suffer from peripheral arterial disease, or PAD, in the United States. PAD is caused by the accumulation of plaque in peripheral arteries – commonly the pelvis or leg – reducing blood flow. Symptoms include leg pain when walking or at rest, and tissue loss that can lead to limb amputation. Many patients with PAD are affected by diabetes, high blood pressure, obesity or renal insufficiency.
Zilver PTX stent is a product of Cook® Medical.
About Metro Health Hospital
Metro Health Hospital is a 208-bed general acute-care osteopathic teaching hospital that serves more than 130,000 patients in Kent and surrounding counties. Metro Health, which earned status as a Top 100 Hospital for the three consecutive years, offers a broad range of services, including inpatient and outpatient services, emergency, surgery, intensive care, rehabilitation, wellness and community education. Metro’s work is supported by the Metro Health Hospital Foundation, which is a charitable organization dedicated to improving the health and well being of the West Michigan community through philanthropy. For more information, visit www.metrohealth.net.